Classic Familial Adenomatous Polyposis Treatment Market size is set to register remarkable growth rate during the forecast period i.e., between 2024-2036.
The growth of the market can be attributed to factors such as the increasing prevalence of colorectal cancer in the world, a personal history of colorectal diseases or polyposis, and growing cases of inherited disorders that heighten the risk of classic FAP. Colorectal cancer is one of the most commonly occurring cancer in the world. In 2018, it was calculated that approximately 1.9 million people globally suffered from the disease. Additionally, excessive intake of tobacco, unhealthy diet and low indulgence in physical activities are considered to be the main causes of FAP. The incidences of sedentary lifestyle are witnessing a notable hike since the last decade, which in turn is expected to drive market growth in the coming years.
Growth Drivers
Challenges
|
Base Year |
2023 |
|
Forecast Year |
2024-2036 |
|
Regional Scope |
|
The market is segmented by drug type into monotherapy drugs and combination therapy drugs, out of which, the segment for monotherapy drugs is anticipated to hold the largest share in the classic familial adenomatous polyposis treatment market during the forecast period on account of their lesser number of adverse effects, reduced treatment costs, better tolerability and enhanced compliance with treatment. Moreover, on the basis of distribution channel, the hospital pharmacy segment is projected to occupy a significant market share in the near future, which can be credited to the increased interaction of prescribers and health professionals in hospitals, improved access to medical records of patients and better input in making effective prescribing decisions about drugs.
Our in-depth analysis of the global classic familial adenomatous polyposis treatment market includes the following segments
|
By Treatment Type |
|
|
By Drug Type |
|
|
By Distribution Channel
|
|
On the basis of geographical analysis, the classic familial adenomatous polyposis treatment market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and the Middle East & Africa. North America is poised to dominate majority revenue share by 2036, on the back of high spending in the healthcare sector, growing occurrence of the disease in the United States and ongoing technological advancements to develop effective cure for colorectal disorders. It is evaluated that FAP affects more than 49, 000 families in the United States. FAP occurs in approximately 1 in every 7000 to 10000 individuals in the country. Furthermore, strong presence of major pharmaceutical companies is also evaluated to drive market growth in the region. Similarly, Europe’s market is also assessed to gather a large classic familial adenomatous polyposis treatment market share owing to the growing investments of key players for drug development in the region.
· September, 2020: Cancer Prevention Pharmaceuticals submitted a new Drug Application to the U.S. Food and Drug Administration (FDA) for CPP-1X/sul for treating familial adenomatous polyposis (FAP) among adults.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?